1-(2-氯乙基)-2-氟苯 | 119779-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-氯乙基)-2-氟苯
• 英文名称: 1-(2-chloroethyl)-2-fluorobenzene
• 英文别名: 2-fluorophenylethyl chloride；2-fluorophenethyl chloride
• CAS: 119779-12-3
• 化学式: C₈H₈ClF
• 分子量: 158.603
• InChiKey: JVLRUIIRRJELIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(4-哌啶)-1H-苯并咪唑 、 1-(2-氯乙基)-2-氟苯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 2-[1-[2-(2-fluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazole
  参考文献：
  名称：

  Orjales; Bordell; Rubio, Journal of Heterocyclic Chemistry, 1995, vol. 32, # 3, p. 707 - 718

  摘要：

  DOI：
• 作为产物：
  描述：

  氯碘甲烷 、 2-氟苯甲醛 在 methyllithium lithium bromide 、 三叔丁基硅烷 、 三(五氟苯基)硼烷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.75h， 以83%的产率得到1-(2-氯乙基)-2-氟苯
  参考文献：
  名称：

  化学选择性的同源脱氧策略，能够使羰基直接转化为（n + 1）-卤代甲基-烷烃。

  摘要：

  据报道，将类胡萝卜素和氢化物顺序安装在羰基上，提供了卤代甲基烷基衍生物。尽管在与以碳为中心的亲电子试剂的反应中使用类胡萝卜素作为亲核试剂，sp 3型烷基卤化物仍然是用于选择性一碳同系物的难以捉摸的材料。我们的策略是利用羰基化合物作为起始原料，从而能够均匀地实现高收率和化学控制。该策略是灵活的，不仅限于类胡萝卜素。而且，各种类似碳负离子的物种可以充当亲核试剂，因此使其具有普遍的适用性。

  DOI：

  10.1021/acs.orglett.0c02831

文献信息

• [EN] MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES<br/>[FR] PIPERIDINES D'ARYLE OU PIPERAZINES SUBSTITUEES PAR DES HETEROCYCLES A 5 RAMIFICATIONS INHIBANT LA MTP
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005085226A1

  公开（公告）日：2005-09-15

  The present invention is concerned with novel aryl piperidine or piperazine compounds substituted with certain 5-membered heterocycles having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes (Formula (I)). The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hyper­triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes.

  本发明涉及新颖的芳基哌啶或哌嗪化合物，其被某些含有apoB分泌/MTP抑制活性和伴随的降脂活性的5-成员杂环取代。该发明还涉及制备这种化合物的方法，包括所述化合物的药物组合物以及将所述化合物用作治疗高脂血症、肥胖症和2型糖尿病的药物的用途（公式（I））。该发明还涉及制备这种化合物的方法，包括所述化合物的药物组合物以及将所述化合物用作治疗动脉粥样硬化、胰腺炎、肥胖症、高甘油三酯血症、高胆固醇血症、高脂血症、糖尿病和2型糖尿病的药物的用途。
• [EN] 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 3-(PYRAZOLYL)-1H-PYRROLO[2,3-B]PYRIDINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014006554A1

  公开（公告）日：2014-01-09

  The present application relates to novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.

  本申请涉及一种新型的3-(吡唑基)-lH-吡咯并[2,3-b]吡啶衍生物，其化学式为(I)，作为蛋白激酶抑制剂。该发明特别涉及化合物的化学式(I)、化合物的制备以及其药物组成。该发明还涉及药用可接受的盐和组合物，包括所述新型的3-(吡唑基)-lH-吡咯并[2,3-b]吡啶衍生物及其在治疗各种疾病中的应用。
• Imidazole derivatives or their salts
  申请人：——

  公开号：US20030176482A1

  公开（公告）日：2003-09-18

  Imidazole derivatives of the formula (1) or salts thereof, pharmaceuticals containing the derivatives or the salts, and intermediates for the synthesis of the derivatives or the salts (wherein R 1 is lower alkyl; R 2 is alkyl or aralkyl; and X 1 is halogeno). These compounds exhibit G-CSF-like activities and can be substituted for G-CSF preparations. 1

  Imidazole衍生物的化学式（1）或其盐，含有这些衍生物或盐的药物，以及用于合成这些衍生物或盐的中间体（其中R1是较低的烷基；R2是烷基或芳基烷基；X1是卤素）。这些化合物表现出类似于G-CSF的活性，并可替代G-CSF制剂。
• Synthesis and biological evaluation of novel triazole derivatives as antifungal agents
  作者：Hui Tang、Can-Hui Zheng、Xiao-Hui Ren、Jia Liu、Na Liu、Jia-Guo Lv、Ju Zhu、You-Jun Zhou

  DOI：10.1016/j.cclet.2013.01.015

  日期：2013.3

  compounds were synthesized and evaluated for their antifungal activities in vitro. The results showed that compounds 6A and 6B exhibited good antifungal activity. Compound 6A8 showed the strongest antifungal activity, which was significantly higher than that of the lead compounds and positive-control drugs Fluconazole and Itraconazole. In particular, the antifungal activity of compound 6A8 against Candida albicans

  合成了一系列的1-（苄氨基）-2-（2,4-二氟苯基）-3-（1 H -1,2,4-三唑-1-基）丙-2-醇化合物，并对其抗真菌性进行了评估体外活动。结果表明，化合物6A和6B表现出良好的抗真菌活性。化合物6A8表现出最强的抗真菌活性，显着高于先导化合物和阳性对照药物氟康唑和伊曲康唑。特别地，化合物6A8对白色念珠菌和克鲁斯念珠菌的抗真菌活性。（MIC80均为0.00097μg/ mL）分别是氟康唑的515倍和64倍。讨论了合成化合物的结构-活性关系，并且目标化合物与真菌羊毛甾醇14对接模型α分析-demethylase（CYP51）。
• Pyrrolo&lsqb;2,3-d&rsqb; pyrimidines as antiviral agents
  申请人：The Regents of the University of Michigan

  公开号：US06342501B1

  公开（公告）日：2002-01-29

  This invention relates to a novel class of 4,5,6,7-substituted non-nucleoside, non-phosphorylatable pyrrolo[2,3-d]pyrimidines which exhibit both significantly lower levels of cytotoxicity and superior antiviral activity than known nucleoside, non-nucleoside, and non-nucleoside, non-phosphorylatable pyrrolo[2,3-d]pyrimidine derivatives, particularly against human DNA viruses such as cytomegalovirus (HCMV) and herpes simplex virus type 1 (HSV-1). These compounds are represented by the following formula: wherein: R4 is —NR1R2 or oxo; R5 is —CN, or —CSNR1R2, or —CONR1R2; R6 is —H, or halo, or —NR1R2; wherein R1 and R2 are independently —H or an aliphatic group; and R7 is of the formula R3—Ar, wherein R3 is an aliphatic group and Ar is an unsubstituted aryl or an aryl independently substituted with halo, nitro, amino, or aliphatic groups; provided that when R5 is a —CN or —CSNH2, and R6 is a —H or —NH2, and Ar is a —C6H5 or a phenyl substituted with only one aliphatic group, R3 is an aliphatic group other than methyl such that —R3— is not a —CH2—; and pharmaceutically acceptable salts, prodrugs and derivatives thereof.

  这项发明涉及一类新型的4,5,6,7-取代的非核苷酸、非磷酸化的吡咯并［2,3-d］嘧啶化合物，这些化合物在人类DNA病毒如巨细胞病毒（HCMV）和单纯疱疹病毒1型（HSV-1）等方面表现出明显较低的细胞毒性和优越的抗病毒活性，优于已知的核苷酸、非核苷酸和非磷酸化的吡咯并［2,3-d］嘧啶衍生物。这些化合物由以下公式表示：其中：R4为—NR1R2或氧；R5为—CN，或—CSNR1R2，或—CONR1R2；R6为—H，或卤素，或—NR1R2；其中R1和R2独立地为—H或脂肪基；R7为R3—Ar的结构，其中R3为脂肪基，Ar为未取代芳基或独立取代有卤素、硝基、氨基或脂肪基的芳基；但当R5为—CN或—CSNH2，且R6为—H或—NH2，Ar为—C6H5或只取代一个脂肪基的苯基时，R3为甲基以外的脂肪基，使得—R3—不是—CH2—；以及其药用盐、前药和衍生物。